SG11201605342UA - Compounds - Google Patents
CompoundsInfo
- Publication number
- SG11201605342UA SG11201605342UA SG11201605342UA SG11201605342UA SG11201605342UA SG 11201605342U A SG11201605342U A SG 11201605342UA SG 11201605342U A SG11201605342U A SG 11201605342UA SG 11201605342U A SG11201605342U A SG 11201605342UA SG 11201605342U A SG11201605342U A SG 11201605342UA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014000139 | 2014-01-29 | ||
PCT/CN2015/000055 WO2015113452A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605342UA true SG11201605342UA (en) | 2016-08-30 |
Family
ID=53756224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605342UA SG11201605342UA (en) | 2014-01-29 | 2015-01-28 | Compounds |
Country Status (20)
Country | Link |
---|---|
US (2) | US10087186B2 (en) |
EP (1) | EP3099695B1 (en) |
JP (1) | JP6422986B2 (en) |
KR (1) | KR20160106622A (en) |
CN (1) | CN105940004B (en) |
AU (2) | AU2015210593A1 (en) |
CA (1) | CA2937431A1 (en) |
CL (1) | CL2016001895A1 (en) |
CR (1) | CR20160348A (en) |
DO (2) | DOP2016000195A (en) |
EA (1) | EA029774B1 (en) |
ES (1) | ES2802174T3 (en) |
IL (1) | IL246579B (en) |
MA (1) | MA39219B1 (en) |
MX (1) | MX367370B (en) |
PE (1) | PE20161443A1 (en) |
PH (1) | PH12016501307B1 (en) |
SG (1) | SG11201605342UA (en) |
UA (1) | UA118369C2 (en) |
WO (1) | WO2015113452A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10339791B2 (en) | 2007-06-12 | 2019-07-02 | Icontrol Networks, Inc. | Security network integrated with premise security system |
CA2937430A1 (en) | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
EP3099695B1 (en) | 2014-01-29 | 2020-04-08 | GlaxoSmithKline Intellectual Property Development Limited | Compounds |
CN105153131B (en) * | 2015-09-21 | 2017-10-17 | 马彦丽 | A kind of pharmaceutical composition that human glioma is treated in nursing |
CN105348270B (en) * | 2015-11-09 | 2018-01-09 | 吕显艳 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
WO2017106771A1 (en) | 2015-12-16 | 2017-06-22 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
CN105418616B (en) * | 2015-12-26 | 2018-01-12 | 山东大学 | A kind of JAK kinase inhibitors containing 4 amino-pyrazol structures and its preparation method and application |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
EP3472153B1 (en) | 2016-06-16 | 2021-09-22 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
BR112019015278A2 (en) * | 2017-01-25 | 2020-04-14 | Glaxosmithkline Ip Dev Ltd | compounds |
WO2018155916A2 (en) * | 2017-02-22 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease |
EP3604304B1 (en) | 2017-03-23 | 2022-09-07 | Daegu-Gyeongbuk Medical Innovation Foundation | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
EA202091372A1 (en) | 2017-12-05 | 2020-10-05 | Оскотек Инк. | PYRROLO (PYRAZOLO) PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR |
CN108715834B (en) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | Preparation method of platelet lysate rich in CD41+ and CD81+ microcapsules |
WO2020036437A1 (en) * | 2018-08-16 | 2020-02-20 | 재단법인 대구경북첨단의료산업진흥재단 | Substituted heteroaryl derivative, method for producing same, and pharmaceutical composition for preventing or treating protein kinase-related diseases which contains same as active ingredient |
US11130752B2 (en) | 2018-09-25 | 2021-09-28 | Cardurion Pharmaceuticals, Llc | Aminopyrimidine compound |
CZ308800B6 (en) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyclic nitrogenous derivatives of purine, pharmaceutical preparations containing these derivatives and their use in neuroprotection |
AU2021371697A1 (en) * | 2020-10-29 | 2023-06-22 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
US11780851B2 (en) | 2021-10-27 | 2023-10-10 | H. Lundbeck A/S | LRRK2 inhibitors |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1675858A2 (en) | 2003-09-03 | 2006-07-05 | Neurogen Corporation | 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
ES2393926T3 (en) | 2004-10-21 | 2013-01-02 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | KASPP gene (LRRK2), its production and use for the detection and treatment of neurodegenerative disorders |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
NO323175B1 (en) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Procedure for showing a mutation that causes hereditary parkinsonism |
EA200800664A1 (en) | 2005-10-13 | 2009-02-27 | Глаксо Груп Лимитед | PYRROPOLYMIDINE DERIVATIVES AS SYK INHIBITORS |
CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
KR20120081609A (en) * | 2009-09-29 | 2012-07-19 | 글락소 그룹 리미티드 | Novel compounds |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PT3124483T (en) * | 2010-11-10 | 2019-10-02 | Genentech Inc | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
ES2553610T3 (en) | 2010-12-14 | 2015-12-10 | Electrophoretics Limited | Casein kinase 1 delta inhibitors (CK1delta) |
KR101649611B1 (en) * | 2011-04-21 | 2016-08-19 | 오리제니스 게엠베하 | Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors |
WO2013042006A1 (en) | 2011-09-22 | 2013-03-28 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
CA2856002C (en) | 2011-11-30 | 2020-10-13 | Bryan K. Chan | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
GB201204985D0 (en) * | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
CN104271569B (en) | 2012-05-03 | 2016-08-24 | 霍夫曼-拉罗奇有限公司 | Pyrazoles aminopyridine derivative as LRRK2 regulator |
MX358172B (en) | 2012-05-03 | 2018-08-08 | Genentech Inc | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease. |
MD20140130A2 (en) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
EP3099695B1 (en) | 2014-01-29 | 2020-04-08 | GlaxoSmithKline Intellectual Property Development Limited | Compounds |
CA2937430A1 (en) | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
-
2015
- 2015-01-28 EP EP15743797.1A patent/EP3099695B1/en active Active
- 2015-01-28 PE PE2016001250A patent/PE20161443A1/en unknown
- 2015-01-28 UA UAA201609099A patent/UA118369C2/en unknown
- 2015-01-28 CN CN201580006361.XA patent/CN105940004B/en not_active Expired - Fee Related
- 2015-01-28 CA CA2937431A patent/CA2937431A1/en not_active Abandoned
- 2015-01-28 KR KR1020167020367A patent/KR20160106622A/en not_active Application Discontinuation
- 2015-01-28 WO PCT/CN2015/000055 patent/WO2015113452A1/en active Application Filing
- 2015-01-28 JP JP2016549028A patent/JP6422986B2/en not_active Expired - Fee Related
- 2015-01-28 EA EA201691514A patent/EA029774B1/en not_active IP Right Cessation
- 2015-01-28 US US15/114,858 patent/US10087186B2/en not_active Expired - Fee Related
- 2015-01-28 MA MA39219A patent/MA39219B1/en unknown
- 2015-01-28 SG SG11201605342UA patent/SG11201605342UA/en unknown
- 2015-01-28 MX MX2016009893A patent/MX367370B/en active IP Right Grant
- 2015-01-28 CR CR20160348A patent/CR20160348A/en unknown
- 2015-01-28 ES ES15743797T patent/ES2802174T3/en active Active
- 2015-01-28 AU AU2015210593A patent/AU2015210593A1/en not_active Abandoned
-
2016
- 2016-06-30 PH PH12016501307A patent/PH12016501307B1/en unknown
- 2016-07-03 IL IL246579A patent/IL246579B/en not_active IP Right Cessation
- 2016-07-26 CL CL2016001895A patent/CL2016001895A1/en unknown
- 2016-07-29 DO DO2016000195A patent/DOP2016000195A/en unknown
-
2018
- 2018-01-12 AU AU2018200277A patent/AU2018200277B2/en not_active Ceased
- 2018-08-02 US US16/052,791 patent/US10618901B2/en active Active
-
2019
- 2019-01-15 DO DO2019000010A patent/DOP2019000010A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181797T1 (en) | Aminopyridyloxypyrazole compounds | |
GB201415573D0 (en) | Compounds | |
SG11201605342UA (en) | Compounds | |
GB201418300D0 (en) | Compounds | |
GB201411418D0 (en) | Compounds | |
GB201410430D0 (en) | Compounds | |
GB201402431D0 (en) | Compounds | |
GB201417369D0 (en) | Compounds | |
GB201404987D0 (en) | Compounds | |
GB201417561D0 (en) | Compounds | |
GB201416186D0 (en) | Compounds | |
GB201406591D0 (en) | Compounds | |
GB201419228D0 (en) | Compounds | |
GB201406956D0 (en) | Compounds | |
AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
GB201419264D0 (en) | Compounds | |
GB201412660D0 (en) | Compounds | |
GB201504956D0 (en) | Compounds | |
GB201419015D0 (en) | Compounds | |
GB201407695D0 (en) | Compounds | |
GB201405361D0 (en) | Compounds | |
GB201707536D0 (en) | Compounds | |
GB201421711D0 (en) | Compounds | |
GB201421020D0 (en) | Compounds | |
GB201421019D0 (en) | Compounds |